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Abstract 
Background: Despite the growing interest in Anderson Fabry disease, uncertainties in terms of 
disease management remain, particularly practical details on use of approved enzyme replacement 
therapy. We report the results of a Delphi consensus panel on the management and therapeutic aspects 
of Fabry disease. 
Methods: A survey designed to gauge consensus among experts involved in the diagnosis and 
treatment of Fabry disease with agalsidase alfa, was compiled and distributed online to 15 experts 
working in Italian Fabry reference centres, and their responses collected and analysed. Statements on: 
1) Diagnosis; 2) Starting ERT; 3) Management of ERT infusion and adverse reactions; and 4) Follow-
up/monitoring of response to therapy and disease progression, were included. Responses without 
consensus discussed with an enlarged Delphi panel of 50 clinicians with the aim of achieving 
consensus. 
Results: All 15 experts responded to the survey. After plenary discussion among the enlarged Delphi 
panel, consensus was reached on most statements. Key points were the use of a target organ biopsy to 
show Gb3 deposits in symptomatic women with no identified pathologic mutation and negative 
molecular analysis, the need for ERT in symptomatic women and in all patients with persistent signs 
and symptoms with or without organ damage. It was agreed to assess vital signs before ERT 
administration and use a 0.2 μL filter on infusion to reduce the risk of adverse reactions. It was agreed 
that serum should be drawn before starting the first infusion, to be stored and analysed for antibodies 
if an adverse reaction occurs, and that pre-medication should be given in patients with history of 
infusion reactions. Holter electrocardiographic monitoring, cardiac and brain magnetic resonance 
imaging, renal parameters, and abdominal ultrasound were considered important for the assessment of 
disease progression and treatment response. 
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Conclusions: In the absence of abundant clinical evidence due to the rarity of this condition, the 
results of this Delphi panel provide welcome guidance to healthcare providers on best practice in the 
management of patients with Fabry disease. Findings from this survey and Delphi panel indicated a 
need for more guidance on some aspects of diagnosis and treatment. 
Keywords: Fabry disease, diagnosis, treatment, management 
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Background 
Despite the growing interest and an increasing amount of published literature [1] and clinical 
data on Anderson Fabry disease – an X-linked progressive multi-organ, metabolic lysosomal 
storage disorder caused by deficiency in the lysosomal enzyme alpha-galactosidase A leading to 
accumulation of glycosphingolipids (mainly globotriaosylceramide or Gb3) throughout the body 
– there are still uncertainties in terms of disease management [2]. In addition, goals of treatment 
are not clearly defined, due in part to the heterogeneity of the disease [3]. Moreover, Fabry 
patients can be treated in a range of settings from specialist reference centres to non-specialist 
therapeutic units, therefore a clear guidance on Fabry Disease is welcome. Current treatments 
consist of enzyme replacement therapy (ERT) and palliative treatments [4-11]. Two ERT drugs 
are available for the treatment of the disease. 
Objectives 
The objective of this paper is to report the results generated by a Delphi consensus panel on 
some unanswered question related to clinical and therapeutic aspects of Fabry disease – 
particularly with respect to agalsidase alfa. 
Method 
The Delphi process 
The rationale for using the Delphi method to achieve consensus has been previously published 
[12, 13]: the Delphi method is a way of collecting opinions from experts – “a Delphi panel” – 
and is widely applied in various fields, including healthcare, to obtain consensus or to provide 
recommendations on a well-defined and specified topic. Although often referred to as a ‘panel’, 
the experts provide their opinions freely, individually and anonymously and this method 
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provides a quick and economic way to contact a large group of experts. 
PHASE 1 – premeeting 
A survey, designed to gauge the level of consensus among a group of expert health 
professionals from well-known centres of excellence in the diagnosis and management of Fabry 
disease, was created by two experts (DC and RP) and distributed online to participating 
clinicians; their responses were then collected anonymously and analysed prior to the enlarged 
meeting. 
Participants voted using a 5-point scale to indicate their level of agreement on each statement (1 
= absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, 5 = absolutely agree). 
Consensus was reached when the sum of items 1 + 2 or 3 + 4 + 5 exceeded 66%. 
The coordinators evaluated the responses and gathered those for which there was no consensus. 
PHASE II – Delphi panel  
Experts from a range of fields participated in the face-to-face Delphi panel discussions, ensuring 
a multidisciplinary approach, and allowing opinions and views from different perspectives to be 
expressed. Participants’ specialty, the number of follow-up patients they have with Fabry 
disease, and the proportion of infused patients, were recorded. 
Statements were divided into 4 main areas: 1) Diagnosis; 2) Starting ERT; 3) Management of 
ERT infusion and adverse reactions with agalsidase alfa; and 4) Tests to evaluate the response 
to therapy and disease progression (follow-up of patients with Fabry disease). Statements 
without consensus were selected for discussion in the Delphi plenary session. After discussion, 
and modification of the statements if required, participants reflected on the comments raised in 
the discussion and voted again using the same 5-point scale. 
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Results 
Participants 
The 15 experts surveyed were from the different specialties involved in the management of 
patients with Fabry disease: nephrology, cardiology, neurology, paediatrics and dermatology. 
Their expertise in dealing with Fabry disease was based on experience gained on diagnosing and 
treating more than three patients. 
Overall consensus 
Four statements for which consensus were not achieved in the survey were selected for 
discussion in the Delphi plenary session of 50 experts. After discussion, and in some cases, 
revision of the statement, second votes were taken on the four statements. After the second vote, 
consensus was reached on one statement; therefore, consensus (>66% either positive or 
negative) was reached on all but three statements according to the pre-defined criteria (Figure 
1). 
Diagnosis of Fabry disease 
There was a negative consensus on four of five statements relating to diagnosis (Figure 2). 
None of the following were regarded as essential for diagnosis: presence of angiokeratoma, 
abdominal ultrasound, renal alteration on echocardiography, and target-organ biopsy showing 
Gb3 deposits in men. 
Regarding the requirement for detecting Gb3 deposits on target-organ biopsy for diagnosis in 
women, the phrase “when they present with signs and symptoms of disease” and “the molecular 
analysis is negative” was added following discussion. Positive consensus was then achieved. In 
addition, during discussion, it also emerged that there was agreement on detecting Gb3 deposits 
in plasma and urine as a less invasive investigation in other patients. 
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Starting ERT in patients with Fabry disease 
Positive consensus was obtained on the initiation of ERT in all symptomatic women and in men 
with persistent signs and symptoms (a new statement added after discussion). Statements 
regarding treating all patients with ERT on diagnosis, and use of ERT only if there is organ 
damage, both achieved negative consensus (Figure 3) [one after revision], and the statement on 
treating all males even if asymptomatic, did not achieve consensus even after discussion 
(Figure 1). 
Management of ERT and adverse reactions in Fabry disease 
Consensus was achieved on all statements (Figure 4), two on the second vote. Participants 
agreed that vital signs – heart rate, blood pressure and body temperature, as well as respiratory 
rate and oxygen saturation (SATO2) – should be measured before and after ERT infusion. 
Positive consensus was achieved after discussion with the immunologist to highlight the 
importance of using an integral 0.2 μL IV filter with the agalsidase alfa infusion line to 
eliminate aggregates, known to be a potential cause of infusion reactions. 
In the event of a mild-to moderate adverse reaction, participants agreed that the infusion should 
be discontinued and restarted at a slower rate once the symptoms had regressed. However, with 
severe adverse reactions all participants agreed that the infusion should be stopped immediately 
and not restarted in the same day. 
The need for determination of antibodies before starting treatment and in the case of an infusion 
reaction also achieved positive consensus. 
Follow-up in Fabry disease 
Ten statements on assessment to be performed at baseline and follow-up achieved positive 
consensus: Holter electrocardiography (ECG), cardiac magnetic resonance imaging (cMRI), 
microalbuminuria assessment, and abdominal echography or ultrasound (Figure 5). Two 
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statements regarding the use of Cystatin C assessment at baseline and follow-up did not achieve 
consensus even after discussion (Figure 1). 
Management of pre-medication 
A section on pre-medication was added and discussed. The results are shown in Figure 6. 
Participants disagreed that pre-medication should always be given before agalsidase alfa 
infusion. Positive consensus was achieved on the other two statements: pre-medication should 
only be given to patients with previous infusion reaction, and the protocol for pre-medication 
adverse reactions should be the same as for other protein preparations. 
Discussion 
In summary, all but four statements achieved consensus in the survey. After discussion of the 
contentious areas, lack of consensus remained for three statements relating to starting ERT in 
men regardless of symptoms, and assessment of Cystatin C at diagnosis or follow-up. There was 
negative consensus on four of five statements and positive consensus on one statement relating 
to diagnosis. Positive consensus was obtained on the initiation of ERT in all symptomatic 
women and in men with persistent signs and symptoms and negative consensus was achieved 
for statements regarding treating all patients with ERT on diagnosis, and use of ERT only if 
there is organ damage. Regarding management of ERT and adverse reactions in Fabry disease, 
consensus was achieved on all statements. In follow-up of patients with Fabry disease, 10 
statements on assessments to be performed at baseline and follow-up achieved positive 
consensus. A section on pre-medication was added and discussed. 
The following provides a brief description of the discussions held on the contentious issues. 
Diagnosis 
All participants agreed after discussion that angiokeratoma is not present in all patients, 
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especially at diagnosis. The presence of angiokeratoma correlates with age, rarely occurring 
during the first 10 years of age, even in males with the classical form of the disease. Its presence 
is dependent on the form of Fabry disease and correlates with severity [14, 15]. 
Although most participants thought that an abdominal ultrasound could be useful in patients 
with suspected renal involvement, but not essential to reach a diagnosis, from the clinical point 
of view, an abdominal ultrasound cannot lead to a differential diagnosis but does provide some 
additional renal information beyond proteinuria. It should be performed in all patients with 
suspected nephropathy regardless of its nature. 
Cardiac involvement is common, but data from the literature show that not all patients have a 
‘renal’ alteration on echocardiography; some patients do not show any cardiac involvement [16, 
17]. 
In symptomatic women with no identified pathologic mutation and negative molecular analysis, 
the use of a target-organ biopsy to show Gb3 deposits could be indispensable. In patients with 
positive molecular analysis, but negative signs and symptoms of illness, the less invasive 
investigation – detection of Gb3 in plasma and urine – can be used. 
Starting ERT 
No consensus was achieved for the statement “ERT should be started always in males, even if 
asymptomatic”; there are very mild mutations which do not cause any signs and symptoms, not 
even in males until they are elderly. Paediatricians make their choice of whether to start ERT 
based on the mutation, signs and symptoms and family history. 
Following discussion, the statement regarding starting ERT only if the parameters suggesting 
organ damage are altered, was rephrased as follows “ERT should be started only when the 
disease involves heart, kidney and brain”. The misleading part of the sentence was ‘organ 
function parameters’ since organ function can involve not only the heart and the kidney, but also 
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hearing impairment, gastrointestinal disorders, quality of life, etc. for which there are no 
numerically measurable parameters. In this revised format, the statement achieved negative 
consensus. However, in view of this discussion, another statement “ERT should be started when 
the patient has persistent signs and symptoms with or without organ damage” was added and 
achieved positive consensus. 
Management of ERT and adverse reactions 
In clinical practice, in addition to standard assessment of BP, HR, and body temperature, most 
clinicians measured respiratory rate and oxygen saturation even in patients with normal 
respiratory function. 
There was some discussion regarding the 79% agreement on the statement about use of an 
infusion line with integral 0.2 μL filter for the administration of agalsidase alfa to reduce 
particulate matter and microaggregates. The immunologists considered this to be of vital 
importance and were surprised that 21% of the clinicians did not agree with this statement, 
given that most infusion reactions are not related to antibody-mediated reactions, but are related 
predominantly to the presence of aggregates in solution. Infusion procedures should be 
standardized for all protein derivatives in order to reduce the risk of adverse events which may 
be related to the presence of aggregates and complexes and The Royal College of Nursing 
Standards for Infusion Therapy state that in-line filtration should be used [18]. In addition to 
these clinical considerations, the agalsidase alfa summary of product characteristics 
recommends the use of a filter [19]; therefore, there could be medical-legal issues if it is not 
used. After discussion, 100% positive consensus was achieved on the second vote. 
For one statement, “I think that antibodies should be determined before starting the treatment”, 
no consensus was achieved at the first vote. The importance of setting a baseline value, by 
which subsequent changes can be compared, was emphasized. From a practical point of view, 
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serum can be taken and stored safely, as antibodies are stable over time, and then analysed if an 
adverse reaction occurs. After discussion, 95% positive consensus was achieved. 
Pre-medication 
Additional discussion on the specific use of pre-medication led to the addition of three 
statements relating to pre-medication, and positive consensus was achieved on the use of pre-
medication only in patients with previous infusion reactions, and use of a standard protocol used 
for other protein preparations in the advent of an adverse reaction with pre-medication. 
Follow-up 
Assessments related to cardiac involvement are particularly useful as abnormalities can be 
detected at an early stage before hypertrophy and fibrosis have developed [20]. Holter ECG 
monitoring is easy to do and it is particularly important in adolescents because clinical trials 
show that heart rate variability is altered in the early stage of disease before onset of 
hypertrophic cardiomyopathy [21]. 
cMRI is also a useful tool for assessing early cardiac involvement at diagnosis because it 
provides additional information to the Holter ECG, such as assessment of cardiac mass and 
detection of left ventricular hypertrophy [22], and can detect the patterns of late gadolinium 
enhancement specific to Fabry disease [22, 23] and has the advantage of being non-invasive. 
cMRI is equally important at follow-up and is especially useful for detecting fibrosis [24]. It 
provides information about disease progression and response to ERT, as patients with severe 
late enhancement do not respond to ERT [25, 26]. The approach for using cMRI for diagnosis 
and follow-up is different in men and women due to gender differences in the patterns of 
cardiomyopathy seen [27]. A clinically important difference (progression or regression) can be 
detected by cMRI in as little as one year. Unfortunately, administration of gadolinium is 
contraindicated in patients with advanced renal insufficiency, so although very useful at follow-
 12 
 
up, it is not always possible in patients with advanced Fabry disease. 
Regarding the assessment of microalbuminuria to detect nephropathy, in children and in all 
patients who do not provide appropriate 24-hour urine samples, an accepted method is to take 
the mean of microalbuminuria values from three consecutive morning urine samples – also 
measuring creatinine at the same time in order to assess the albumin-creatinine ratio; this 
method is used in patients with other diseases such as diabetes [28]. 
The use of brain MRI was discussed at length. It is considered to be useful at follow-up for 
monitoring of CNS damage, but not essential. A parenchymal MRI at follow-up is useful to 
determine if and when new ischemic lesions appear in order to associate them with clinical 
signs which may appear later on. 
Lack of consensus 
There was no consensus on three statements even after the plenary discussion and second 
voting. The statement “Enzyme replacement therapy should always be started in males, even if 
asymptomatic” reflects the previously discussed fact that mutations in males can cause a mild 
phenotype, only developing signs or symptoms at advanced age. 
Although there was no consensus on the statements concerning assessment using Cystatin C at 
diagnosis (“I think it is essential to assess Cystatin C at patient diagnosis”) and follow-up (“I 
think it is essential to assess Cystatin C at patient follow-up”) due to variations in practice, it 
was pointed out that it could be a more appropriate test than glomerular filtration rate or 
creatinine serum level for monitoring the effect of treatment on renal function over time; 
therefore, clinicians should evaluate Cystatin C every 6 or 12 months [29-32]. Even if Cystatin 
C is tested only in specific high-risk patients (i.e. transplant patients), being an expensive 
examination, the importance of Cystatin C was emphasized and clinicians were urged to 
consider its use in a Fabry laboratory panel. 
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Conclusions 
The Delphi method was used to obtain consensus on best practice on a range of topics related to 
diagnosis and treatment of patients with Fabry disease. The method is well known for its 
robustness in making highly valid and unbiased consensus findings. The clinical 
recommendations of the Delphi panel experts are summarized as follows: 
1. Diagnosis must be suspected in individuals of both sexes who show suggestive 
symptoms of Fabry disease independently of the presence of angiokeratoma, or renal 
alterations on echocardiography. A biopsy of target organs to detect Gb3 deposits 
should be performed to reach diagnosis in symptomatic women with no identified 
pathologic mutation and negative molecular analysis. In other patients, the less invasive 
method of detecting Gb3 in plasma and urine can be used. 
2. ERT must be started in all women and men with persistent signs and symptoms. 
3. Always use an infusion line with integral 0.2 μL filter for administration of ERT. 
4. A blood sample must be drawn and serum stored for baseline antibodies. It will be sent 
to the laboratory together with another sample taken only in the case of a reaction. 
5. As far as agalsidase alfa is concerned, the use of premedication is recommended only if 
the patient has had previous reactions. 
6. The 6- and 12-month follow up of the Fabry patient should include Holter monitoring, 
cMRI, microalbuminuria, and abdominal echography and brain MRI. 
The results of this Delphi panel provide welcome guidance to healthcare providers on best 
practice in the management of patients with Fabry disease. The outcomes of this Delphi Panel 
shows some aspects of diagnosis and overall management of Fabry disease need to be improved 
and should be addressed further. 
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Figure legends 
Figure 1 Statements on Fabry disease for which there was no consensus. The proportions of 
respondents responding absolutely disagree/disagree and agree/more than agree/absolutely agree 
shown as a percentage. Absolute numbers of votes are also shown on the bars. 
Figure 2 Responses to statements on the diagnosis of patients with Fabry disease. The 
proportions of respondents responding absolutely disagree/disagree and agree/more than 
agree/absolutely agree shown as a percentage. Absolute numbers of votes are also shown on the 
bars. 
Figure 3 Responses to statements on starting enzyme replacement therapy (ERT) in 
patients with Fabry disease. The proportions of respondents responding absolutely 
disagree/disagree and agree/more than agree/absolutely agree shown as a percentage. Absolute 
numbers of votes are also shown on the bars. 
Figure 4 Responses to statements on the management of enzyme replacement. therapy 
(ERT) infusion and adverse reactions in patients with Fabry disease. The proportions of 
respondents responding absolutely disagree/disagree and agree/more than agree/absolutely agree 
shown as a percentage. Absolute numbers of votes are also shown on the bars. 
Figure 5 Responses to statements on the follow-up of patients with Fabry disease. The 
proportions of respondents responding absolutely disagree/disagree and agree/more than 
agree/absolutely agree shown as a percentage. Absolute numbers of votes are also shown on the 
bars. 
Figure 6 Responses to added statements on the management of pre-medication in patients 
with Fabry disease. The proportions of respondents responding absolutely disagree/disagree 
and agree/more than agree/absolutely agree shown as a percentage. Absolute numbers of votes 
are also shown on the bars. 
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Table 
Table 1 Clinical recommendations 
Diagnosis In women presenting with signs and symptoms of disease, no pathologic 
mutation and negative molecular analysis, a Gb3 biopsy is essential. In other 
patients, a less invasive option of detecting Gb3 in plasma and urine can be 
useful. 
Starting ERT Enzyme replacement therapy should be started when the patient has persistent 
signs and symptoms with or without organ damage 
Management 
of ERT 
agalsidase 
alfa infusion 
and adverse 
reactions 
It is important to assess vital signs (BP, HR, respiratory rate, SATO2) and 
temperature before the administration of ERT 
Use of an infusion line with integral filter (for 0.2 μL intravenous infusion) is 
recommended 
Collect and store sample before the first infusion is started, so that antibody 
values can be evaluates if any adverse event occurs 
Premedication should only be given to patients with previous infusion reaction 
with therapeutic approach similar to the one used for other protein infusion 
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Pre-
medication 
Before agalsidase alfa infusion, pre-medication should only be given in 
patients who have previously had an infusion reaction 
In case of adverse reactions with the pre-medication, the same protocol as for 
the other protein preparations should be followed 
Follow-up At baseline and 6/12 months’ follow-up the following are essential: 
 Holter monitoring to detect changes in heart rate variability 
 Cardiac magnetic resonance imaging 
 Microalbuminuria 
 Abdominal echography 
 Brain magnetic resonance imaging 
There was NO consensus on assessment using Cystatin C 
 
